Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Ung

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
American Health & Drug Benefits|December 22, 2017
The Value of Pre-FDA Approval Healthcare Economic Information Exchange Between Payers and Drug ManufacturersPeter R Fendt, Brian Ung, F Randy Vogenberg
Current Medical Research and Opinion|September 14, 2019
Treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriatic arthritis: results from a US claims analysisJashin J Wu, Corey Pelletier, Brian Ung, et al.
Journal of Medical Economics|January 18, 2019
Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasisJashin J Wu, Corey Pelletier, Brian Ung, et al.
Future Oncology (London, England)|October 19, 2019
Lenalidomide maintenance post-transplantation in newly diagnosed multiple myeloma: real-world outcomes and costsParameswaran Hari, Brian Ung, Safiya Abouzaid, et al.
Journal of Comparative Effectiveness Research|July 18, 2025
Real-world phosphorodiamidate morpholino oligomer treatment patterns in Duchenne muscular dystrophy: a claims-based analysisShannon Grabich, Brian Ung, Aalok Nadkar, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 13, 2018
Assessing the Effect of Adherence on Patient-reported Outcomes and Out of Pocket Costs Among Patients With Multiple MyelomaShaloo Gupta, Safiya Abouzaid, Ryan Liebert, et al.
Journal of Comparative Effectiveness Research|July 9, 2020
Real-world switch patterns and healthcare costs in biologic-naive psoriasis patients initiating apremilast or biologicsJashin J Wu, Corey Pelletier, Brian Ung, et al.
Advances in Therapy|March 7, 2020
Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic ArthritisJashin J Wu, Corey Pelletier, Brian Ung, et al.
Journal of Managed Care & Specialty Pharmacy|September 26, 2017
Performance-Based Risk-Sharing Arrangements: U.S. Payer ExperienceJoseph A Goble, Brian Ung, Sascha van Boemmel-Wegmann, et al.
Advances in Therapy|August 19, 2023
Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa TrialNovember McGarvey, Brian Ung, Thomas Carattini, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
American Health & Drug Benefits|December 22, 2017
The Value of Pre-FDA Approval Healthcare Economic Information Exchange Between Payers and Drug ManufacturersPeter R Fendt, Brian Ung, F Randy Vogenberg
Current Medical Research and Opinion|September 14, 2019
Treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriatic arthritis: results from a US claims analysisJashin J Wu, Corey Pelletier, Brian Ung, et al.
Journal of Medical Economics|January 18, 2019
Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasisJashin J Wu, Corey Pelletier, Brian Ung, et al.
Future Oncology (London, England)|October 19, 2019
Lenalidomide maintenance post-transplantation in newly diagnosed multiple myeloma: real-world outcomes and costsParameswaran Hari, Brian Ung, Safiya Abouzaid, et al.
Journal of Comparative Effectiveness Research|July 18, 2025
Real-world phosphorodiamidate morpholino oligomer treatment patterns in Duchenne muscular dystrophy: a claims-based analysisShannon Grabich, Brian Ung, Aalok Nadkar, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 13, 2018
Assessing the Effect of Adherence on Patient-reported Outcomes and Out of Pocket Costs Among Patients With Multiple MyelomaShaloo Gupta, Safiya Abouzaid, Ryan Liebert, et al.
Journal of Comparative Effectiveness Research|July 9, 2020
Real-world switch patterns and healthcare costs in biologic-naive psoriasis patients initiating apremilast or biologicsJashin J Wu, Corey Pelletier, Brian Ung, et al.
Advances in Therapy|March 7, 2020
Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic ArthritisJashin J Wu, Corey Pelletier, Brian Ung, et al.
Journal of Managed Care & Specialty Pharmacy|September 26, 2017
Performance-Based Risk-Sharing Arrangements: U.S. Payer ExperienceJoseph A Goble, Brian Ung, Sascha van Boemmel-Wegmann, et al.
Advances in Therapy|August 19, 2023
Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa TrialNovember McGarvey, Brian Ung, Thomas Carattini, et al.
Pageof 2